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I am responding to your letter regarding the skin lesion local medical reyiew policy 
(LMRP) issued by the Medicare carrier, Blue Cross and Blue Shield of Florida 
(FL BC/BS). 
The general concerns of the dermatology community are that implementation of the skin 
lesion LMRP represents a major change from existing Medicare policy, circumvents 
physician judgement, and may put beneficiaries at risk. At present there is no specific 
national policy for removal of skin lesions ( e.g., actinic keratoses ). Under Medicare 
guidelines, removal of skin lesions is covered when medically necessary. The skin lesion 
LMRP, based on a review of published literature, describes when it is medically 
necessary to surgically remove actinic keratoses. In asymptomatic actinic keratosis, 
surgery is medically unnecessary except in certain, specified situations. We reviewed the 
Florida policy and believe it is medically sound. The process used by FL BC/BS in 
developing and implementing the policy was in accordance with Medicare's LMRP 
process. Additionally, the Health Care Financing Administration's (HCF A's) medical 
officers reviewed the skin lesion LMRP and believe that, based on the literature, it is 
clinically sound. The carrier is declining coverage of procedures that do not meet the 
standards in section 1862 (a)(l)(A) of the Social Security Act (the Act), which requires 
that services be "reasonable and necessary," and section 1862(a)(10) of the Act, that 
·excludes most cosmetic surgery. 
Both HCF A and FL BC/BS invited the dermatology community to come forward with 
literature supporting the medical necessity for destruction of asymptomatic actinic 
keratosis in cases other than those printed by the Florida LMRP. To date, neither HCFA 
nor the carrier has received such literature. 
This policy in no way circumvents physician judgement. The skin lesion LMRP seeks to 
articulate when surgical destruction ( e.g., laser treatment, chemical treatments) is ~ 
medically necessary. There are clinical criteria cited in the skin lesion LMRP that 
constitute appropriateness. In those cases, Medicare will pay for the procedure. Several 
of the criteria are : 
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• When the patient presents with an actinic keratosis that has changed in size, has 
developed erythema, has thickened, has ulcerated, has eroded, has developed 
changes at the tumor margins, has become markedly hyperkeratotic, in -which pain 
has developed, or a cutaneous horn has developed; 
• When the patient presents with an actinic keratosis of the lower-lip, upper-lip, 
conjunctivae, nose, ear, or eyelid; 
• When the patient presents with an actinic keratosis and has a history of one of the 
following: chronic immunosuppression, treatment of psoriasis with psolaren- . 
ultraviolet A (PUV A) therapy, xeroderma pigmentosum, albinism, discoid lupus 
erythematosus, or previous treatment of a biopsy-proven Squamous Cell 
Carcinoma or other skin malignancy; . 
• When a patient presents with an actinic keratosis and has a history of significant 
exposure to therapeutic or occupational radiation therapy; . 
• When the patient has multiple actinic keratoses and has self-administered 
2 percent to 5 percent Efudex topical cream for two to four weeks and the actinic 
keratoses have not responded to this treatment one to two months following 
treatment. 
There has been considerable misunderstanding of the reference to Efudex, so allow me to 
clarify an important point. A fundamental principle in the policy is that treatment of 
asymptomatic actinic keratosis is medically unnecessary. This would be true for-any 
method of treatment, e.g., surgical, laser, or cryogenic destructio~ or use of topical 
creams (chemical destruction). Because literature indicates that lesions failing topical 
treatment with Efudex suggest a higher likelihood of malignancy, the carrier allowed for 
coverage in these cases. In other words, a failure of Efudex establishes a lesion as being 
suspicious versus asymptomatic. 
LMRP is generally developed to specify criteria that describe whether the item/service is 
covered and under what clinical circumstances Medicare coverage is reasonable, 
necessary and appropriate. · Medicare contractors often set local policy priorities gased on 
data analysis which shows utilization and payment data relative to national utilization and 
payment data. Where services in a contractor's locale are significantly higher than the 
national average, the contractor must make a reasonable effort to identify the cause of the 
aberrancy. When the contractor believes that a LMRP is needed, the contractor is 
required to follow a formal process. Carriers develop and implement LMRPs in 
accordance with instructions published in the Medicare Carrier Manual. 
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,. The actions of FL BC/BS are in accordance with program instructions provided by 
HCF A. Approximately $40 million was paid in Florida over a 1-year period for 3 
procedure codes used in billing for removal of 2.2 million benign skin lesions. The most 
common diagnosis listed in billing for these procedures was actinic keratoses. The 
average payments for these 3 procedures per 1,000 Medicare enrollees in Florida ~as the 
highest in the country ($9,688), approximately 3 times the national average. · 
On November 15, HCFA staff met with representatives of the American Academy-of 
Dermatology (AAD) to discuss the medical indications for treatment of actinic keratoses. 
HCFA proposed to present this topic to HCFA's Technical Advisory Committee (TAC) 
and the representatives from AAD agreed to provide literature that supports their position. 
When the literature is provided by AAD for presentation to the TAC, the TAC will 
review it and determine if a national skin lesion policy is warranted. Fallowing the 
TAC's recommendation, HCFA will respond accordingly. If a national policy is 
established, it will take precedence over any local or model policies regarding the 
removal of skin lesions. 
The Florida skin lesion LMRP lays out the criteria for when surgical destruction of skin 
lesions is medically necessary. The skin lesion LMRP both reduces inappropriate billing 
and protects beneficiaries from procedures that are not medically necessary. Should 
additional information become available, providers are always free to contact the carrier 
and request policy changes. In addition, HCF A continues to offer formal appeal rights to 
providers who believe their claims are denied because of contractor error. 
I hope this response addresses your concerns. 
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